What is Harrow Health Inc. 11.875% Senior Notes due 2027's current stock price?

Harrow Health Inc. 11.875% Senior Notes due 2027 (HROWM) currently trades at USD 26.03. Track real-time price changes and historical performance on AllInvestView.

What sector is Harrow Health Inc. 11.875% Senior Notes due 2027 in?

Harrow Health Inc. 11.875% Senior Notes due 2027 operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Harrow Health Inc. 11.875% Senior Notes due 2027 HROWM · Stock Open Harrow Health Inc. 11.875% Senior Notes due 2027 in new tab

26.03 USD

Add to portfolio

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Harrow Health Inc. 11.875% Senior Notes due 2027 (HROWM)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Harrow Health Inc. 11.875% Senior Notes due 2027 Analysis (HROWM)

United States Health Care Official Website Stock

Is Harrow Health Inc. 11.875% Senior Notes due 2027 a good investment? Harrow Health Inc. 11.875% Senior Notes due 2027 (HROWM) is currently trading at 26.03 USD.

Investor FAQ

Does Harrow Health Inc. 11.875% Senior Notes due 2027 pay a dividend?

No, it does not currently pay a dividend.

What asset class is Harrow Health Inc. 11.875% Senior Notes due 2027?

Harrow Health Inc. 11.875% Senior Notes due 2027 is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Exchange Ticker

NMS (United States) HROWM

Trades

Dividend History paid per year (USD)

Historical Dividends

Year	Total Dividends
▸2025	2.23 USD
July 31, 2025	0.7422
April 30, 2025	0.7422
Jan. 31, 2025	0.7422
▸2024	2.97 USD
Oct. 31, 2024	0.7422
July 31, 2024	0.7422
April 30, 2024	0.7422
Jan. 31, 2024	0.7422
▸2023	2.56 USD
Oct. 31, 2023	0.7422
July 13, 2023	0.7422
April 30, 2023	0.7422
Jan. 31, 2023	0.3381

Harrow Health Inc. 11.875% Senior Notes due 2027 HROWM · Stock Open Harrow Health Inc. 11.875% Senior Notes due 2027 in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Harrow Health Inc. 11.875% Senior Notes due 2027 Analysis (HROWM)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Harrow Health Inc. 11.875% Senior Notes due 2027 HROWM · Stock Open Harrow Health Inc. 11.875% Senior Notes due 2027 in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Harrow Health Inc. 11.875% Senior Notes due 2027 Analysis (HROWM)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications